Foundayo Becomes First Oral GLP-1 Weight Loss Pill Without Fasting Requirement

The FDA approved Eli Lilly's Foundayo (orforglipron) on April 1, making it the first oral GLP-1 weight loss drug that patients can take at any time of day without restricting food or water. The distinction matters clinically: Orforglipron is a small molecule that the body can absorb quickly and get into the blood without the fasting requirements that bind oral peptide GLP-1 formulations, a structural advantage over the Wegovy pill from Novo Nordisk, which requires patients to avoid eating or drinking for 30 minutes after each dose. Wegovy pill, from Novo Nordisk, was the first oral GLP-1 drug approved by the FDA, in December 2025. Foundayo is the second.

The efficacy case for Foundayo carries weight but also caveats. The ATTAIN clinical program, enrolling more than 4,500 patients, demonstrated 12.4% mean weight loss at 72 weeks among completers at the highest dose, equating to an average of 27.3 pounds compared to 2.2 pounds on placebo. Novo plans to argue that the Wegovy pill is more effective, having shown around 16.6% weight loss on average in a late-stage trial. Still, Deborah Horn, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, said the oral medication offers patients "greater flexibility in how they approach their treatment."

The safety profile follows GLP-1 class conventions with one hard stop. Foundayo's label carries a boxed warning, the FDA's most serious label addition, advising of an increased risk of thyroid C-cell tumors. The drug is contraindicated in patients with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2. Additional warnings cover pancreatitis, acute gallbladder disease, and hypoglycemia. Common side effects include nausea, constipation, vomiting, and diarrhea.

The patient access picture depends almost entirely on insurance status. Eligible patients with commercial insurance may pay as little as $25 per month with a savings card, while self-pay patients can access the drug starting at $149 per month for the lowest dose. Eligible Medicare Part D patients may access the medication for $50 per month beginning as soon as July 1, 2026. Lilly said Foundayo would be available via LillyDirect with prescriptions accepted immediately and free home delivery beginning April 6, followed by broader availability through retail pharmacies and telehealth providers. The $149 self-pay floor applies only to the lowest starting dose; as with all GLP-1 therapies, most patients titrate upward over time, which raises out-of-pocket costs for the uninsured significantly.

The speed of the approval itself carries its own controversy. The FDA issued its decision 50 days after filing, 294 days before Foundayo's PDUFA date of January 20, 2027, marking the fastest approval of a new molecular entity since 2002. It was cleared as the first new molecular entity approved under the Commissioner's National Priority Voucher pilot program, introduced in June 2025 and designed to compress review timelines from the standard 10-12 months to as little as 1-2 months. Democratic Representative Jake Auchincloss has said the CNPV program is "shrouded in secrecy," with regulatory and biopharma leaders attempting to decode the criteria for receiving a voucher. A PBS NewsHour investigation found that access to FDA Commissioner Makary is limited because he does not use a government email account for business, breaking with longstanding precedent, and that once a voucher is awarded, some drugmakers have their own interpretation of the review timeline, creating confusion and anxiety among staff.

The market stakes behind that expedited process are enormous. Lilly has already amassed $1.5 billion worth of Foundayo inventory ahead of launch. The trio of Mounjaro, Zepbound, and Foundayo could net Lilly $101 billion in peak worldwide revenue. Lilly CEO David Ricks has noted that fewer than one in ten people who could benefit from a GLP-1 therapy are currently taking one, citing access barriers, stigma, and the complexity of existing treatment options. Whether Foundayo's pill format expands that number meaningfully, or simply shifts existing users away from injectable competitors, will hinge on whether insurers decide a no-fasting convenience premium is worth covering at scale.